8-K: Vicarious Surgical Implements 1-for-30 Reverse Stock Split and Increases Equity Incentive Plan Shares

Vicarious Surgical Inc. has completed a 1-for-30 reverse stock split and increased the number of shares available under its equity incentive plan following shareholder approval at its annual meeting.

Summary

• Vicarious Surgical Inc. held its annual meeting on June 10, 2024, where shareholders approved a reverse stock split and an increase in the company's equity incentive plan.
• The board approved a 1-for-30 reverse stock split, which became effective on June 12, 2024, at 4:15 p.m. Eastern Time.
• Prior to the split, there were 156,762,690 shares of Class A common stock and 19,619,760 shares of Class B common stock outstanding.
• After the reverse stock split, there are approximately 5,225,423 shares of Class A common stock and 653,992 shares of Class B common stock outstanding.
• The total number of authorized shares remained the same, and the par value and voting rights of the common stock were unchanged.
• The exercise price of warrants was adjusted to $345.00 per share, with the number of shares they can purchase reduced to approximately 921,620.
• The company's 2021 Equity Incentive Plan was amended to increase the number of shares available by 5,000,000, which was adjusted to 166,666 shares after the reverse stock split.
• Shareholders also ratified the appointment of Deloitte & Touche LLP as the company's independent auditor for the fiscal year ending December 31, 2024.

Sentiment

Score: 5

Explanation: The document primarily details a reverse stock split and an adjustment to the equity incentive plan, which are neutral to slightly negative events. The reverse stock split is often a sign of a struggling stock price, but the increase in the equity plan could be seen as a positive for future growth.

Positives

• The reverse stock split was approved by shareholders, indicating support for the company's strategic direction.
• The increase in shares available under the equity incentive plan may help attract and retain talent.
• The company has ratified the appointment of Deloitte & Touche LLP as their independent auditor, ensuring financial oversight.

Negatives

• The reverse stock split significantly reduced the number of outstanding shares, which could be perceived negatively by some investors.
• The increase in the warrant exercise price to $345.00 may make them less attractive to holders.

Risks

• The reverse stock split could lead to increased volatility in the stock price.
• The adjusted warrant terms may impact investor sentiment and warrant trading activity.
• The company's future performance will be critical to maintaining investor confidence after the reverse stock split.

Management Comments

• The Board approved effecting the Proposed Reverse Stock Split, effective as of June 12, 2024, and fixed a ratio for the reverse stock split at 1-for-30.

Industry Context

Reverse stock splits are often used by companies to increase their stock price and maintain listing requirements on major exchanges. This action is not uncommon in the biotech and medical device industry, especially for companies that have experienced a decline in share price.

Comparison to Industry Standards

• Reverse stock splits are a common mechanism for companies facing delisting from major exchanges due to low share prices, similar to actions taken by other companies in the biotech and medical device sectors.
• The 1-for-30 ratio is a significant split, which is on the higher end compared to some other reverse stock splits, which often range from 1-for-2 to 1-for-10.
• Companies like Cassava Sciences and Ocugen have also recently undertaken reverse stock splits to maintain their listing status, demonstrating a similar trend in the industry.

Stakeholder Impact

• Shareholders will see a reduction in the number of shares they own, but the value of their holdings should remain relatively constant immediately after the split.
• Employees with stock options or grants will see an adjustment in the number of shares and exercise price.
• Warrant holders will have their exercise price adjusted and the number of shares they can purchase reduced.

Next Steps

• The company's Class A common stock will continue to trade on the New York Stock Exchange under the symbol RBOT on a post-split basis.
• The company's public warrants will continue to be traded under the symbol RBOT WS.

Key Dates

Keywords

reverse stock split, equity incentive plan, warrants, shareholder meeting, common stock, Deloitte & Touche, corporate governance